Category: Insights

Biosimilars in Developed and Developing East and Southeast Asian Countries: Japan, South Korea, and Malaysia—Overview, Evolution, and Regulations Assessment

This is paper was originally published in BioMed Research International, Volume 2016, by Tomas Gabriel Bas and Carolina Oliu Castillo under a Creative Commons Attribution License Abstract The development of…
The post Biosimilars in Developed and Develo…


Evolving Pharmaceutical Strategies in a Post-Blockbuster World

Headlines about high drug prices are nothing new. The high cost of bringing new drugs to market, plus high merger and acquisition activity in pharmaceuticals have led to price increases…
The post Evolving Pharmaceutical Strategies in a Post-Blockbuster…


Balancing Opportunity and Risk in India’s Pharmaceutical Sector

India’s pharmaceutical industry has grown tremendously over the past thirty years and is now the world’s third largest drug producer as measured by volume. Hyderabad is one of India’s major…
The post Balancing Opportunity and Risk in India’s Pharmaceut…


Patents for Personalized Medicine: Challenges and Opportunities

Combination products are a key aspect of personalized medicine, offering more targeted treatment to patients The era of personalized medicine approaches more closely with each passing day, and with it…
The post Patents for Personalized Medicine: Challe…


Affordability and availability of off-patent drugs in the United States—the case for importing from abroad: observational study

This article was originally published by Ravi Gupta, Thomas J Bollyky, Matthew Cohen, Joseph S Ross, and Aaron S Kesselheim  in BMJ 2018;360:k831 under a Creative Commons Attribution Non Commercial (CC BY-NC…
The post Affordability and availability of …


What We Know From 4-Plus Years of Drug Patent Challenges Heard by the PTAB

While the Patent Trial and Appeal Board invalidates Orange Book-listed patents less than 20 percent of the time, it accepts 66 percent of petitions from generic drugmakers and takes no…
The post What We Know From 4-Plus Years of Drug Patent Chall…


How Pharmaceutical Blockchain Technology Challenges Can Be Overcome

By Ed Lamb, DrugPatentWatch Writer Pilot projects are underway, but regulatory and stakeholder buy-in concerns remain When pharmaceutical supply chain stakeholders met recently to discuss applications for blockchain technology, they…
The post How…


Do NOT follow this link or you will be banned from the site!